Cardinal Health Inc vs InMode Ltd — how do they compare? Cardinal Health Inc trades at $228.8 (market cap $53.89B), while InMode Ltd trades at $15 (market cap $857.04M). The key difference: Cardinal Health Inc is far larger — about 62.9× InMode Ltd's market cap, and Cardinal Health Inc pays a 0.89% dividend while InMode Ltd pays none. Which is the better fit depends on your goals.
| CAH | INMD | |
|---|---|---|
Market Cap | $53.89B | $857.04M |
Sector | Health | Technology |
52-Week High | $239.71 | $16.62 |
52-Week Low | $146.04 | $12.76 |
Enterprise Value | $58.87B | $324.71M |
Dividend Yield | 0.89% | — |
Signals from Pluang's Aura AI — not financial advice
Cardinal Health (CAH) trades at $233.66, down 0.91% in the last session, with a bullish technical signal from moving averages and strong analyst support. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $3.17 surpassing expectations. Revenue reached $222.58 billion in 2025, though net margins remain thin at 0.62%. Recent news highlights growth potential in medical supplies, with earnings results for fiscal 2026 due August 11.
The outlook for CAH is positive, driven by earnings momentum and sector tailwinds, but risks include high leverage with debt-to-asset ratio at 16.09% and competitive pressures. Analyst consensus is bullish with a $248 price target, suggesting 6% upside. Investors should weigh solid operational cash flow against negative shareholder equity and investing outflows.
INMD trades at $15.15, down 0.85% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company maintains strong profitability with a 77.84% gross margin and a P/E of 11.04, indicating potential undervaluation. Recent news includes an unsolicited acquisition offer at $16.75 per share and upcoming Q2 2026 earnings on August 5, 2026, with revenue guidance of $95.2M-$95.4M.
The outlook is mixed: solid fundamentals and a takeover bid provide upside potential, but risks include earnings misses, legal investigations, and shareholder opposition to the acquisition. Analyst consensus is a $16.50 price target with a balanced buy/hold split, suggesting cautious optimism amid near-term volatility.
Trailing returns across standard periods
Latest headlines on both assets
Cardinal Health is a leading pharmaceutical wholesaler, engaged in the sourcing and distribution of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail-order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and McKesson, the three compose well over 90% of the U.S. pharmaceutical wholesale industry. Cardinal Health also supplies medical-surgical products and equipment to healthcare facilities in North America, Europe, and Asia.
Read more on CAH →InMode provides innovative medical technologies for minimally invasive surgical procedures. Its platforms use radiofrequency (RF) energy for aesthetic treatments like body contouring and skin tightening.
Read more on INMD →